AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 104 filers reported holding AKERO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10 | +11.1% | 188 | 0.0% | 0.00% | – |
| Q2 2023 | $9 | +28.6% | 188 | 0.0% | 0.00% | – |
| Q1 2023 | $7 | -30.0% | 188 | 0.0% | 0.00% | – |
| Q4 2022 | $10 | -99.8% | 188 | +58.0% | 0.00% | – |
| Q3 2022 | $4,000 | +300.0% | 119 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | -50.0% | 119 | 0.0% | 0.00% | – |
| Q1 2022 | $2,000 | -33.3% | 119 | 0.0% | 0.00% | – |
| Q4 2021 | $3,000 | 0.0% | 119 | 0.0% | 0.00% | – |
| Q3 2021 | $3,000 | +50.0% | 119 | +83.1% | 0.00% | – |
| Q2 2021 | $2,000 | 0.0% | 65 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | 0.0% | 65 | 0.0% | 0.00% | – |
| Q4 2020 | $2,000 | -60.0% | 65 | -59.6% | 0.00% | – |
| Q3 2020 | $5,000 | +66.7% | 161 | 0.0% | 0.00% | – |
| Q2 2020 | $3,000 | 0.0% | 161 | 0.0% | 0.00% | – |
| Q1 2020 | $3,000 | -25.0% | 161 | 0.0% | 0.00% | – |
| Q4 2019 | $4,000 | – | 161 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |